A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes-Reference-Cited by-同舟云学术

A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes

Published:2010-03 Issue:2 Volume:34 Page:145-154
ISSN:0896-8411
Container-title:Journal of Autoimmunity
language:en
Short-container-title:Journal of Autoimmunity

Author:

Scheuplein Felix,Rissiek Björn,Driver John P.,Chen Yi-Guang,Koch-Nolte Friedrich,Serreze David V.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference38 articles.

1. Expression of ADP-ribosyltransferase on normal T lymphocytes and effects of nicotinamide adenine dinucleotide on their function;Okamoto;J Immunol,1998

2. Generation and characterization of ecto-ADP-ribosyltransferase ART2.1/ART2.2-deficient mice;Ohlrogge;Mol Cell Biol,2002

3. NAD-induced T cell death: aDP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor;Seman;Immunity,2003

4. CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins;Krebs;J Immunol,2005

5. Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion;Chen;J Immunol,2006

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice;Journal of Nanobiotechnology;2024-01-11

2. Tumour immune escape via P2X7 receptor signalling;Frontiers in Immunology;2023-10-30

3. Antibodies as Therapeutic Agents;Protein-based Therapeutics;2023

4. Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo;Frontiers in Immunology;2022-10-19

5. P2X7 receptor as the regulator of T-cell function in intestinal barrier disruption;World Journal of Gastroenterology;2022-09-28